Singapore markets closed
Straits Times Index
3,095.59 -6.62 (-0.21%) Nikkei
25,935.62 -457.42 (-1.73%) Hang Seng
21,859.79 -137.10 (-0.62%) FTSE 100
7,168.65 -0.63 (-0.01%) BTC-USD
19,231.01 -1,190.29 (-5.83%) CMC Crypto 200
420.84 +0.70 (+0.17%)
Viatris Inc. (VTRS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 10.47 |
| Open | 10.45 |
| Bid | 10.47 x 900 |
| Ask | 10.70 x 21500 |
| Day's range | 10.28 - 10.74 |
| 52-week range | 9.66 - 15.60 |
| Volume | |
| Avg. volume | 11,537,391 |
| Market cap | 12.984B |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | 76.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.48 (4.58%) |
| Ex-dividend date | 23 May 2022 |
| 1y target est | N/A |
- CNW Group
Viatris and Biocon Biologics Launch Abevmy® (Bevacizumab), Their Third Oncology Biosimilar, in Canada
Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin® (bevacizumab) and has been approved by Health Canada across four oncology indications.
- Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm
LOS ANGELES, September 29, 2021--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc.
© 2022 Yahoo. All rights reserved.
